Literature DB >> 17393967

Symptom clusters in patients with high-grade glioma.

Sherry W Fox1, Debra Lyon, Elana Farace.   

Abstract

PURPOSE: To describe the co-occurring symptoms (depression, fatigue, pain, sleep disturbance, and cognitive impairment), quality of life (QoL), and functional status in patients with high-grade glioma.
DESIGN: Correlational, descriptive study of 73 participants with high-grade glioma in the U.S.
METHODS: Nine brief measures were obtained with a mailed survey. Participants were recruited from the online message board of The Healing Exchange BRAIN TRUST, a nonprofit organization dedicated to improving quality of life for people with brain tumors.
FINDINGS: Two symptom cluster models were examined. Four co-occurring symptoms were significantly correlated with each other and explained 29% of the variance in QoL: depression, fatigue, sleep disturbance, and cognitive impairment. Depression, fatigue, sleep disturbance, cognitive impairment, and pain were significantly correlated with each other and explained 62% of the variance in functional status.
CONCLUSIONS: The interrelationships of the symptoms examined in this study and their relationships with QoL and functional status meet the criteria for defining a symptom cluster. The differences in the models of QoL and functional status indicates that symptom clusters may have unique characteristics in patients with gliomas.

Entities:  

Mesh:

Year:  2007        PMID: 17393967     DOI: 10.1111/j.1547-5069.2007.00144.x

Source DB:  PubMed          Journal:  J Nurs Scholarsh        ISSN: 1527-6546            Impact factor:   3.176


  50 in total

1.  Symptom clusters and prognosis in advanced cancer.

Authors:  Aynur Aktas; Declan Walsh; Lisa Rybicki
Journal:  Support Care Cancer       Date:  2012-02-24       Impact factor: 3.603

Review 2.  Systematic review of supportive care needs in patients with primary malignant brain tumors.

Authors:  Elizabeth Ford; Susan Catt; Anthony Chalmers; Lesley Fallowfield
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

Review 3.  Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Authors:  Dina Randazzo; Katherine B Peters
Journal:  CNS Oncol       Date:  2016-07-11

4.  Symptom-based interventions to promote quality survivorship.

Authors:  Christina Amidei
Journal:  Neuro Oncol       Date:  2018-11-09       Impact factor: 12.300

5.  Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma.

Authors:  Karin Gehring; Martin J B Taphoorn; Margriet M Sitskoorn; Neil K Aaronson
Journal:  Neurooncol Pract       Date:  2015-03-03

6.  Recurrent brain tumour: the impact of illness on patient's life.

Authors:  Elena Lamperti; Giuseppe Pantaleo; Claudia Yvonne Finocchiaro; Antonio Silvani; Andrea Botturi; Paola Gaviani; Lucio Sarno; Andrea Salmaggi
Journal:  Support Care Cancer       Date:  2011-07-03       Impact factor: 3.603

7.  Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Authors:  Terri S Armstrong
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

8.  Predicting distress among people who care for patients living longer with high-grade malignant glioma.

Authors:  B Russell; A Collins; A Dowling; M Dally; M Gold; M Murphy; J Burchell; J Philip
Journal:  Support Care Cancer       Date:  2015-04-25       Impact factor: 3.603

9.  Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report.

Authors:  Stefanie Schreiber; Vanessa Prox-Vagedes; Erck Elolf; Ines Brueggemann; Guenther Gademann; Imke Galazky; Claudius Bartels
Journal:  BMC Cancer       Date:  2010-10-01       Impact factor: 4.430

Review 10.  Long-term Survivors of Childhood Brain Tumors: Impact on General Health and Quality of Life.

Authors:  Priyamvada Gupta; Rakesh Jalali
Journal:  Curr Neurol Neurosci Rep       Date:  2017-11-08       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.